Korean Journal of Anesthesiology



Review Article

DOI: https://doi.org/10.4097/kja.23530
Tranexamic acid - a promising hemostatic agent with limitations: a narrative review
Dong Joon Kim, Su Yeon Cho, Ki Tae Jung 
Department of Anesthesiology and Pain Medicine, Chosun University Hospital, College of Medicine and Medical School, Chosun University, Gwangju, Korea
Corresponding author: Ki Tae Jung ,Tel: +82-62-220 3223, Fax: +82-62-223-2333, Email: mdmole@chosun.ac.kr
Received: July 7, 2023;  Accepted: August 21, 2023.
Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that has been used for several decades to reduce blood loss during surgery and after trauma. TXA was traditionally used to reduce bleeding in various clinical settings such as menorrhagia, hemophilia, or other bleeding disorder . Numerous studies have demonstrated the efficacy of TXA in reducing blood loss and the need for transfusions. Interest in the potential applications of TXA beyond its traditional use has been growing recently, with studies investigating the use of TXA in postpartum hemorrhage, cardiac surgery, trauma, neurosurgery, and orthopedic surgery. Despite its widespread use and expanding indications, data regarding the safe and appropriate use of TXA is lacking. Recent clinical trials have found various potential risks and limitations in the long-term benefits of TXA. This narrative review summarizes the clinical applications and limitations of TXA.

Keywords :Blood transfusion; Cardiac surgical procedures; Hemorrhage; Neurosurgery; Orthopedic procedures; Postpartum hemorrhage; Tranexamic acid; Trauma

Go to Top